Development of nanobodies that target amyloid- oligomers for individual diagnosis in Alzheimers disease

Project: Research project

Project Details

Description

Development of nanobodies that target amyloid- oligomers for individual diagnosis in Alzheimers disease Development of nanobodies that target amyloid- oligomers for individual diagnosis in Alzheimer?s disease In the proposed project, the Sierks lab will further assess nanobodies A4, E1, and C6 as deliverables that target AD-specific oligomeric A as diagnostic biomarkers. We will test these antibodies for reactivity with various CSF samples obtained from the Mayo Clinic. One bank maintained by Dr. Steven Younkin includes samples from AD patients and age-matched controls (20 of each). A second bank maintained by Dr. Ronald Petersen as part of a study on aging includes 500-600 samples, mostly from patients with mild cognitive impairment or normal controls but also 30 samples from patients who have advanced to AD. These samples will be used only for validation after assay development is completed with the Younkin bank.
StatusFinished
Effective start/end date2/1/131/31/15

Funding

  • Mayo Clinic Jacksonville: $50,000.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.